The oncogenic BRAF V600E mutation causes constitutive activation of the Ras-Raf-MEK-ERK (RAS) signaling pathway, stimulating cellular growth, differentiation and survival.1 Although rare in multiple myeloma, this mutation has attracted attention because of its proven potential for targeted inhibition. This evidence concerns the gene BRAF and plasma cell myeloma.